PF-Atlas › Clinical Trials › NCT03094169

AVID100 in Advanced Epithelial Carcinomas

AVID100 IV · Phase 1

Registry ID

NCT03094169

Phase

Phase 1

Status

Terminated

Drug / intervention

AVID100 IV

Sponsor

Formation Biologics

Start

2017-02-01

Enrollment

Locations

About this trial

Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is available, will be entered into this Phase 1a/2a, multicenter, open-label, dose-escalation, cohort study of AVID100. Phase 2a will include evaluation of patient with EGFR-overexpressing squamous histology non-small cell lung cancer, squamous cell carcinoma of the head and neck, and triple negative breast cancer

View NCT03094169 on ClinicalTrials.gov →

Explore related

All AVID100 IV trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT03094169 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.